Servier completes its retreat from cell therapy
The sale of remaining rights to Allogene ends acrimony between the two companies.
FDA critics barely lay a glove on Geron
Imetelstat appears headed for approval after its US adcom turns into a damp squib.
Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
New phase 1 projects enter hot fields
Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.
Cellectis gets another bailout
Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.
Sana shelves its in vivo Car-T
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.
Lilly calls time on IDH1/2 inhibition
Servier's vorasidenib had shown promise at ASCO, but Lilly's dual IDH project LY3410738 leaves the pipeline.
